Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study

Hematological Oncology - United Kingdom
doi 10.1002/hon.114_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Cost-Effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Journal of Health Economics and Outcomes Research
2016English

Investigating Safety and Preliminary Efficacy of Afm13 Plus Pembrolizumab in Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy
OncologyPharmacology
2014English

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy